Rockefeller Capital Management
ADPT icon

Rockefeller Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Rockefeller Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$368K Sell
17,163
-100
-0.6% -$1.53K ﹤0.01% 2250
2026
Q1 		$240K Buy
17,263
+9,686
+128% +$154K ﹤0.01% 2387
2025
Q4 		$123K Buy
7,577
+2,550
+51% +$41.6K ﹤0.01% 2617
2025
Q3 		$75.2K Buy
+5,027
New +$61.3K ﹤0.01% 2723
2024
Q1 		– Sell
-76,798
Closed -$376K – 1660
2023
Q4 		$376K Sell
76,798
-43,615
-36% -$199K ﹤0.01% 1414
2023
Q3 		$656K Sell
120,413
-32,668
-21% -$216K ﹤0.01% 1229
2023
Q2 		$964K Sell
153,081
-11,873
-7% -$88.3K ﹤0.01% 1101
2023
Q1 		$1.46M Sell
164,954
-1,610
-1% -$14.2K 0.01% 933
2022
Q4 		$1.27M Sell
166,564
-10,549
-6% -$82.1K 0.01% 918
2022
Q3 		$1.26M Sell
177,113
-10,748
-6% -$101K 0.01% 930
2022
Q2 		$1.52M Sell
187,861
-39
-0% -$343 0.01% 849
2022
Q1 		$2.61M Buy
187,900
+22,532
+14% +$354K 0.01% 713
2021
Q4 		$4.64M Buy
165,368
+33,527
+25% +$1.03M 0.02% 564
2021
Q3 		$4.48M Buy
131,841
+3,727
+3% +$135K 0.02% 505
2021
Q2 		$5.23M Sell
128,114
-551,449
-81% -$21.4M 0.03% 442
2021
Q1 		$27.4M Buy
679,563
+638,841
+1,569% +$34.6M 0.19% 130
2020
Q4 		$2.41M Buy
40,722
+17,562
+76% +$906K 0.02% 482
2020
Q3 		$1.13M Buy
23,160
+14,520
+168% +$610K 0.01% 570
2020
Q2 		$418K Buy
8,640
+4,800
+125% +$175K ﹤0.01% 766
2020
Q1 		$107K Buy
3,840
+3,248
+549% +$90.6K ﹤0.01% 995
2019
Q4 		$18K Sell
592
-383
-39% -$11K ﹤0.01% 1422
2019
Q3 		$30K Buy
+975
New +$39.8K ﹤0.01% 1109

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Rockefeller Capital Management's ADPT Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Adaptive Biotechnologies (ADPT) stake by 0.58% in Q2 2026, selling an estimated $1.53K and leaving 17,163 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #2250.

Rockefeller Capital Management first reported a position in ADPT in Q3 2019 and has held it in 22 quarters since. The position peaked at $27.4M in Q1 2021. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Rockefeller Capital Management held 17,163 shares of Adaptive Biotechnologies worth $368K as of Q2 2026.
  • Rockefeller Capital Management sold 100 Adaptive Biotechnologies shares in Q2 2026, an estimated $1.53K.
  • Adaptive Biotechnologies made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2250 holding.
  • Rockefeller Capital Management first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 22 quarters since.
  • Rockefeller Capital Management's Adaptive Biotechnologies position peaked at $27.4M in Q1 2021.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.